CompletedNot applicableNCT01954641
Official study title

Accountability for Cancer Care Through Undoing Racism and Equity

Study summary

Purpose: African American cancer patients, as compared to their White counterparts, continue to initiate treatment later and remain less apt to undergo complete treatment; fueling worse treatment outcomes including shorter survival. The concepts of "transparency" and "accountability," as mechanisms of systems change have been applied for decades by anti-racism organizations to civil rights and social change. Yet, the application of these concepts to health systems' change and unequal treatment has rarely been done. The Greensboro Health Disparities Collaborative and two Cancer Centers have joined together to specify structures built into cancer care systems that make cancer care vulnerable to institutional racism and investigate how they can be changed to reduce racial inequity in quality and completion of treatment for Stage 1-2 breast and lung cancer patients. Participants: White and African American patients with first diagnosis of Stage 1-2 breast and lung cancer, with intention to treat, and their cancer care staff at 2 cancer centers. The 2 cancer centers are Cone Health Cancer Center (CHCC) in Greensboro, North Carolina and the University of Pittsburgh Medical Center (UPMC) Hillman Comprehensive Cancer Center in Pittsburgh, Pennsylvania. Procedures (methods): Using a 5-year interrupted time-series, with an embedded randomized control trial (RCT) study design, we will test the effectiveness of the ACCURE intervention components. Having received Institutional Review Board approval for Phase 1, we completed a 5-year, retrospective review of de-identified Electronic Medical Record data to establish a baseline of repeated outcome measures, convening of an expert committee to design the intervention, and design of the real-time, electronic breast and lung cancer registry coupled with dummy testing of the registry system. The randomized trial will compare patients who receive usual care to those who receive visits and calls from a trained ACCURE Navigator, who is well versed in issues specific to breast and lung cancer and trained to serve as a two-way communication bridge to optimize the cancer care system's accountability and transparency for equity in quality of care. Given unintended, but likely variation in implementation of the ACCURE intervention by the two Cancer Centers (at our two research sites), 6 elements of implementation and their potential effect on outcomes will be documented through a process evaluation.

Ask AI to explain this study
Start here

Key things to know

Main goalHealth Services Research

This describes the study’s primary purpose.

What is being studiedACCURE Navigator and Usual Care by Cancer Center Care Team

The study team can explain what participation involves.

Who it may be forEarly-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 1, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?University of North Carolina, Chapel Hill

Study sponsor

01
Study overview

What this study is about

Purpose
Health Services Research
Study type
Interventional
Phase
Not applicable
Sponsor
University of North Carolina, Chapel Hill
Interventions being studied
Other: ACCURE Navigator; Other: Usual Care by Cancer Center Care Team
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • White or African American patients aged 18 or older
  • Recently received a first diagnosis of stage 1 or 2 breast or lung cancer
  • Patient plans to initiate oncology treatment with curative intent
Reasons someone may not be able to joinExclusion criteria

Have cognitive impairments or limited English proficiency that would preclude their ability to comprehend survey questions

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Cone Health, Regional Cancer CenterGreensboro, North Carolina
  • University of Pittsburgh Medical Center, Hillman Comprehensive Cancer CenterPittsburgh, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 1, 2018. Always confirm current availability with the study team.

View original record ↗